Animal health company Zoetis (NYSE: ZTS) fell short of the market’s revenue expectations in Q2 CY2026, with sales flat year on year at $2.47 billion. The company’s full-year revenue guidance of $9.22 billion at the midpoint came in 5.4% below analysts’ estimates. Its non-GAAP profit of $1.87 per share was 1% above analysts’ consensus estimates.

Is now the time to buy ZTS? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Zoetis delivered flat revenue in Q2, missing Wall Street expectations, while its adjusted earnings per share slightly exceeded consensus. The market’s positive reaction was underpinned by management’s acknowledgment of intensifying competitive pressures in key Companion Animal categories and ongoing declines in U.S. veterinary clinic visits. CEO Kristin Peck noted, “Veterinary clinic visits declined across markets, extending a multiyear trend that has occurred alongside price increases that have outpaced broader consumer inflation.” The company highlighted resilience in its Livestock and Diagnostics segments, despite softness within dermatology and parasiticides.

Looking forward, Zoetis lowered its full-year revenue and profit guidance, citing continued competition and value-conscious behavior from pet owners. Management plans to sharpen commercial execution, enhance cost discipline, and accelerate innovation, especially within its dermatology and diagnostics portfolios. Peck explained, “We are responding with focus and discipline, sharpening execution in Companion Animal, allocating capital with discipline, exercising greater cost discipline, and continuing to advance the innovation that has always differentiated Zoetis.” The company’s revised outlook reflects expectations that current headwinds in the U.S. Companion Animal market will persist into the second half of the year.

Key Insights from Management’s Remarks

Management attributed Q2 performance to sustained U.S. clinic traffic declines, increased promotional activity in core categories, and shifts in leadership designed to improve execution and agility.

• U.S. Companion Animal Weakness: The company saw continued declines in U.S. veterinary clinic visits, particularly affecting premium therapies in dermatology and parasiticides. Management highlighted that “pet owners have become more selective in how they spend,” leading to pressure in key franchises like Apoquel and Simparica Trio.
• Elevated Competition and Promotions: Zoetis reported intensified competition, with new entrants aggressively using discounts and rebates in a stagnating market. Peck emphasized that this dynamic is not expanding the market, but instead increasing pressure on existing players.
• Cost Discipline and Strategic Investments: The company reduced operating expenses by 2% and SG&A by 4% year-over-year, reflecting deliberate cost actions. CFO Wetteny Joseph noted, “We continue to demonstrate strong P&L discipline, protecting profitability through cost actions while staying focused on the investment behind our highest-return opportunities.”
• Leadership Changes: Zoetis promoted Abhay Nayak to EVP and President of U.S. Commercial Operations to drive performance in its largest market. Additionally, Jay Saccaro will become EVP, Chief Financial Officer, and Chief Operating Officer to improve decision-making and operational agility.
• Diagnostics and Livestock Resilience: The Diagnostics segment grew 12% on sustained demand for urgent care tools, and Livestock posted strong 11% growth, particularly in cattle and poultry products. Management sees these segments as stabilizing forces amid Companion Animal pressures.

Drivers of Future Performance

Zoetis’ updated outlook is shaped by persistent competitive activity, ongoing cost controls, and selective investments in product innovation.

• Sustained Competitive Pressure: Management assumes that heightened price promotions and new market entrants in dermatology and parasiticides will continue, requiring aggressive gross-to-net investments to defend share and limit volume declines.
• Cost Management Initiatives: Zoetis is prioritizing cost containment, including targeted reductions in discretionary spending and further SG&A efficiency, to offset margin pressures. However, it intends to maintain R&D and commercial investments in high-potential franchises to support future growth.
• Pipeline and Launch Execution: The company aims to bolster growth with anticipated approvals and launches, such as the long-acting Cytopoint for dermatology and the continued rollout of Vetscan OmniMax in diagnostics. Management believes these innovations can help offset market pressures and drive long-term recovery.

Catalysts in Upcoming Quarters

In the coming quarters, our analysts will closely watch (1) stabilization or recovery in U.S. veterinary clinic visits and premium therapy demand, (2) the pace of new product launches in dermatology and diagnostics, and (3) the effectiveness of leadership changes in driving commercial execution. Additionally, the StockStory team will monitor ongoing cost discipline efforts and the competitive landscape for signs of easing promotional activity.

Zoetis currently trades at $77.20, up from $74.40 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).

Our Favorite Stocks Right Now

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.